STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADPT
  4. [Form 4] Adaptive Biotechnologies Corp Insider Trading Activity

[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp’s Chief People Officer reported stock option exercises and a share sale. On December 15, 2025, the officer exercised options to acquire a total of 97,022 shares of common stock at exercise prices of $7.8, $8.46, and $3.99 per share. On the same date, 113,890 shares were sold in an open-market transaction at a weighted-average price of $15.57, with individual sale prices ranging from $15.37 to $16.03, all under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following these transactions, the reporting person directly beneficially owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse, and continued to hold multiple vested stock options.

Positive

  • None.

Negative

  • None.
Insider LO FRANCIS
Role Chief People Officer
Sold 113,890 shs ($1.77M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 37,750 $0.00 --
Exercise Stock Option (right to buy) 19,423 $0.00 --
Exercise Stock Option (right to buy) 39,849 $0.00 --
Exercise Common Stock 37,750 $7.80 $294K
Exercise Common Stock 19,423 $8.46 $164K
Exercise Common Stock 39,849 $3.99 $159K
Sale Common Stock 113,890 $15.57 $1.77M
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 113,250 shares (Direct); Common Stock — 370,596 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LO FRANCIS
(Last) (First) (Middle)
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVE E
(Street)
SEATTLE WA 98109
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief People Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 M(1) 37,750 A $7.8 370,596 D
Common Stock 12/15/2025 M(1) 19,423 A $8.46 390,019 D
Common Stock 12/15/2025 M(1) 39,849 A $3.99 429,868 D
Common Stock 12/15/2025 S(1) 113,890 D $15.57(2) 315,978 D
Common Stock 2,500 I By You Jin Lee (spouse)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $7.8 12/15/2025 M(1) 37,750 (3) 05/06/2029 Common Stock 37,750 $0 113,250 D
Stock Option (right to buy) $8.46 12/15/2025 M(1) 19,423 (4) 03/06/2033 Common Stock 19,423 $0 109,176 D
Stock Option (right to buy) $3.99 12/15/2025 M(1) 39,849 (5) 03/04/2034 Common Stock 39,849 $0 110,175 D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
2. The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. The option is fully vested and exercisable.
4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
5. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact 12/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Adaptive Biotechnologies (ADPT) report in this Form 4?

The Chief People Officer of Adaptive Biotechnologies Corp reported exercising stock options to acquire a total of 97,022 shares of common stock and selling 113,890 shares on December 15, 2025.

At what prices were the Adaptive Biotechnologies (ADPT) stock options exercised and shares sold?

The options were exercised at prices of $7.8, $8.46, and $3.99 per share. The 113,890 shares sold had a weighted-average price of $15.57 per share, with individual sale prices between $15.37 and $16.03.

Was the Adaptive Biotechnologies (ADPT) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

How many Adaptive Biotechnologies (ADPT) shares does the reporting person own after these transactions?

After the reported transactions, the insider beneficially owned 315,978 shares of common stock directly and 2,500 shares indirectly through a spouse.

What stock options does the Adaptive Biotechnologies (ADPT) insider continue to hold?

The filing shows remaining vested stock options to purchase common stock, including positions with exercise prices of $7.8, $8.46, and $3.99 per share, with expiration dates in 2029, 2033, and 2034, respectively.

How are the vesting terms of the Adaptive Biotechnologies (ADPT) options described?

One option grant is fully vested and exercisable, while other grants vested as to 1/4 of the shares on specific March vesting dates, with the remaining shares vesting in 1/48 monthly installments of continuous service until fully vested.